Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.

American journal of hematology - 1 Jan 2014

Helbig Grzegorz, Kyrcz-Krzemień Sławomira

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Hypereosinophilic Syndrome
Share to Imatinib Mesylate
Share to mRNA Cleavage and Polyadenylation Factors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Oncogene Proteins, Fusion

Share to Piperazines

Share to Receptor, Platelet-Derived Growth Factor alpha

Share to Remission Induction

Source

Identifiers

PMID: 24009127
DOI: 10.1002/ajh.23588

Genes

PDGFRA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.PMID 24009127Read ↗

Exquisite response to imatinib mesylate in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome: a 12-year experience of the Polish Hypereosinophilic Syndrome Study Group.Semantic proximity Read ↗

Maintenance therapy with imatinib appears necessary despite molecular remission in FIP1L1-PDGFRA fusion gene positive hypereosinophilic disorder.Semantic proximity Read ↗

Allogeneic bone marrow transplantation for hypereosinophilic syndrome: long-term follow-up with eradication of FIP1L1-PDGFRA fusion transcriptSemantic proximity Read ↗

Imatinib for the treatment of hypereosinophilic syndromes.Semantic proximity Read ↗

Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders.Semantic proximity Read ↗

Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRalpha-negative hypereosinophilic syndrome.Semantic proximity Read ↗

Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome.Semantic proximity Read ↗

The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and managementSemantic proximity Read ↗

Imatinib therapy in a patient with suspected chronic neutrophilic leukemia and FIP1L1-PDGFRA rearrangement.Semantic proximity Read ↗

[FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutant of PDGFRA gene: a case report and literature review].Semantic proximity Read ↗

Idiopathic Hypereosinophilic Syndrome in ChildrenSemantic proximity Read ↗

FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.